Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Arcus Biosciences, Inc. (RCUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
4
| Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Sold 21,369 shares
@ $19.99, valued at
$427.2k
|
|
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2023 |
SC 13D/A
| GILEAD SCIENCES, INC. reports a 35% stake in ARCUS BIOSCIENCES, INC. |
| 07/05/2023 |
4
| Azoy Alexander (Chief Accounting Officer) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Sold 1,018 shares
@ $20.41, valued at
$20.8k
|
|
| 06/30/2023 |
4
| GILEAD SCIENCES, INC. (10% Owner) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Bought 1,010,000 shares
@ $19.26, valued at
$19.5M
|
|
| 06/16/2023 |
4
| Tang Carolyn C. (General Counsel) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Disposed/sold 2,892 shares
@ $19.35, valued at
$56k
|
|
| 06/16/2023 |
4
| Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Sold 12,563 shares
@ $19.35, valued at
$243.1k
|
|
| 06/16/2023 |
4
| Jaen Juan C. (President) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Gifted 6,000 shares
@ $0
Disposed/sold 4,820 shares
@ $19.35, valued at
$93.3k
|
|
| 06/16/2023 |
4
| ROSEN TERRY J (CEO) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Disposed/sold 8,762 shares
@ $19.35, valued at
$169.5k
|
|
| 06/16/2023 |
4
| Lambert Nicole (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| PERLMAN ANDREW J (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| Lacey David L. (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| Ribas Antoni (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| Machado Patrick (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Gifted 50,504 shares
@ $0
Granted 6,800 shares
@ $0
Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac...|
Docs:
|
"ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 15, 2023 A. Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $25,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer for Chair of Compensation Committee: $15,000 5. Additional retainer for Chair of Nominating and Corporate Governance Committee: $10,000 6. Additional retainer for non-Chair members of Audit Committee: $10,000 7. Additional retainer for non-Chair members of Compensation Committee: $7,500 8. Additional retainer for non-Chair member of Nominating and Corporate Governance Committee: $5,000 B. E..." |
|
| 06/09/2023 |
4
| Goeltz II Robert C. (CFO) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Sold 4,049 shares
@ $20.04, valued at
$81.1k
|
|
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/15/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/20/2023 |
4
| Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.|
Txns:
| Sold 8,729 shares
@ $16.81, valued at
$146.7k
|
|
| 03/10/2023 |
3
| Azoy Alexander (Chief Accounting Officer) has filed a Form 3 on Arcus Biosciences, Inc. |
| 03/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 3.7% stake in Arcus Biosciences, Inc. |
|
|
|